Sign In
AKCA.US
id: 318
It is still possible to file a late claim. The court will decide whether to accept late claims or not.
Delaware court of Chancery
Court
19 Jul 2017
Class period Start
12 Oct 2020
Class period End
11 Oct 2022
Claim deadline
Akcea agreed to pay $12.5 million to settle a securities class action lawsuit.

The original complaint alleged that the Company's Director and Ionis as the majority stockholder of Akcea breached their fiduciary duties in connection with the Merger, including by, among other things, not properly accounting for the value of claims brought in the Derivative Litigation when negotiating the $18.15 price to be paid in the Merger.

Akcea agreed to settle with investors to avoid further litigation.
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
John Makris, Sean Sego, Omar Wever-Pinzon, Jordan Schlee
Attorneys
Labaton Sucharow LLP
Judge
Hon.Lori Will
Administrator
A.B. Data Ltd
Court hearing date
11 October 2022
+$12,500,000
Cash Settlement Amount

Akcea Therapeutics Inc

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally....

    Ticker
    AKCA.US
    ISIN
    US00972L1070
    CIK
    1662524
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    22 Boston Wharf Road, Boston, MA, United States, 02210